BOLERO-2 - will this change practice in advanced breast cancer?
The benefit of endocrine therapy has always been limited by the eventual development of acquired resistance. For the first time, clinical research has identified a therapeutic agent, everolimus, that targets the mammalian target of rapamycin (mTOR), which in combination with the aromatase inhibitor exemestane can substantially reduce the risk of disease progression and seemingly circumvent endocrine resistance. The magnitude of the benefit represents a quantum shift in how we should use endocrine therapy in future, and potentially defines a new standard of care in this setting.
The Royal Marsden NHS Foundation Trust, Fulham Road, Chelsea, London, SW3 6JJ, UK. stephen.johnston@rmh.nhs.uk
Stephen Rd
SR
Johnston
D000730:Androstadienes / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D000068338:Everolimus; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*
D000730:Androstadienes; D047072:Aromatase Inhibitors; D007166:Immunosuppressive Agents; D000068338:Everolimus; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; C056516:exemestane; D020123:Sirolimus